Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI for Injection) for the Combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Facial wrinkles; Glabellar lines
  • Focus Therapeutic Use
  • Sponsors Revance Therapeutics

Most Recent Events

  • 25 Jan 2021 According to a Revance Therapeutics media release, data from this trial will be presented at the Derm for Dermatologists 2021 meeting being held in-person at the Grand Wailea in Maui, Hawaii and broadcasted via live-stream for those unable to join in person.
  • 07 Jan 2021 According to an Revance Therapeutics media release, the company plans to submit the result of this study at a 2021 medical conference and peer review submissions.
  • 22 Dec 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top